{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Esther Wollert",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2012-2018 Fraunhofer Institute SCAI, All rights reserved",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "ECCODE": "^\\d+\\.-\\.-\\.-|\\d+\\.\\d+\\.-\\.-|\\d+\\.\\d+\\.\\d+\\.-|\\d+\\.\\d+\\.\\d+\\.(n)?\\d+$",
      "TAXONOMY": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/501ceccdc9a27d97edbdc48a89ebe8e1dd3626e9/export/conso.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/1b7e14ec0fd02ee7ed71514c6e267f57d5641a4b/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/hgnc-symbols.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "INTERPRO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-20170731.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/mesh-names.belns",
      "MGI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20170725.belns",
      "RGD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20170725.belns"
    },
    "path": "receptors/mandrekar2011.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Alzheimer’s disease (AD) is the leading cause of dementia in the elderly.",
      "key": "bbdb112fe2ebdaa48a8b8f1f57b4c68b",
      "line": 62,
      "relation": "increases",
      "source": 75,
      "target": 78
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "AD is a chronic neurodegenerative disease characterized by the progressive deposition of the amyloid b (Ab) in the parenchyma of the brain.",
      "key": "e04ba413a0146bc9b67f57a5714b434d",
      "line": 67,
      "relation": "association",
      "source": 75,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The ApoE4 allele is most important genetic risk factor for AD, while the ApoE2 allele is thought to be protective. ",
      "key": "62649290feb376d9748dc4bff14f9ab4",
      "line": 165,
      "relation": "positiveCorrelation",
      "source": 75,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The ApoE4 allele is most important genetic risk factor for AD, while the ApoE2 allele is thought to be protective.",
      "key": "b9c974c932adf281ec09454ea1a30a7f",
      "line": 466,
      "relation": "association",
      "source": 75,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "  In this study, it was shown that samples from human AD brains as well as two aged mouse models of AD showed increased mRNA levels of the M2 markers, Arg1 and Ym1, when compared to age matched controls [101].",
      "key": "31f11834d35f15e67dce7c52bc891521",
      "line": 407,
      "relation": "positiveCorrelation",
      "source": 75,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "  In this study, it was shown that samples from human AD brains as well as two aged mouse models of AD showed increased mRNA levels of the M2 markers, Arg1 and Ym1, when compared to age matched controls [101].",
      "key": "202af1c304af5bf23d09e0064fcf1f02",
      "line": 408,
      "relation": "positiveCorrelation",
      "source": 75,
      "target": 81
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "AD is a chronic neurodegenerative disease characterized by the progressive deposition of the amyloid b (Ab) in the parenchyma of the brain.",
      "key": "ed04209ba1ba4633d644e14a633e08ea",
      "line": 67,
      "relation": "association",
      "source": 13,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "It has been postulated that soluble or small oligomeric forms of Ab have deleterious effects in the brain, inducing impaired synaptic function and promoting neuronal degeneration [5]. ",
      "key": "953079387a66e1d64f573945fca0f03a",
      "line": 73,
      "relation": "decreases",
      "source": 14,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "It has been postulated that soluble or small oligomeric forms of Ab have deleterious effects in the brain, inducing impaired synaptic function and promoting neuronal degeneration [5]. ",
      "key": "0c911c15f2c6ab693da7ce1af50146bf",
      "line": 75,
      "relation": "increases",
      "source": 14,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "It has been postulated that soluble or small oligomeric forms of Ab have deleterious effects in the brain, inducing impaired synaptic function and promoting neuronal degeneration [5]. ",
      "key": "ef3e81ffcd105ce2b75c327d45f48b9e",
      "line": 74,
      "relation": "decreases",
      "source": 16,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "It has been postulated that soluble or small oligomeric forms of Ab have deleterious effects in the brain, inducing impaired synaptic function and promoting neuronal degeneration [5]. ",
      "key": "e05a8d67794ea6780829ac5845f712c9",
      "line": 76,
      "relation": "increases",
      "source": 16,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The development of dense-core amyloid plaques is associated with a robust immune response mediated by microglial cells.",
      "key": "e96d96ea467d11c480bde8ae174b47d7",
      "line": 81,
      "relation": "association",
      "source": 17,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The appearance of amyloid deposition in the AD brain coincides with a dramatic phenotypic activation of microglial cells in the surrounding area.",
      "key": "1b0d594166528bdc464a89188bd0e363",
      "line": 387,
      "relation": "positiveCorrelation",
      "source": 17,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The plaque-associated microglia secrete a variety of cytotoxic species including the inflammatory cytokines, INF-g, TNF-a, IL-1b and IL-6 and chemokines, most prominently CCL2 [10-12]. ",
      "key": "38e6c41ce53be153955fee120d813503",
      "line": 88,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 17,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The plaque-associated microglia secrete a variety of cytotoxic species including the inflammatory cytokines, INF-g, TNF-a, IL-1b and IL-6 and chemokines, most prominently CCL2 [10-12]. ",
      "key": "cc78dbe847223e7564439fe8e5f43c56",
      "line": 89,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 17,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The plaque-associated microglia secrete a variety of cytotoxic species including the inflammatory cytokines, INF-g, TNF-a, IL-1b and IL-6 and chemokines, most prominently CCL2 [10-12]. ",
      "key": "be2e6add412f670b74e03c3ffc196198",
      "line": 90,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 17,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The plaque-associated microglia secrete a variety of cytotoxic species including the inflammatory cytokines, INF-g, TNF-a, IL-1b and IL-6 and chemokines, most prominently CCL2 [10-12]. ",
      "key": "6558b67060f503b0103e36a9f9edbbf9",
      "line": 91,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 17,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The plaque-associated microglia secrete a variety of cytotoxic species including the inflammatory cytokines, INF-g, TNF-a, IL-1b and IL-6 and chemokines, most prominently CCL2 [10-12]. ",
      "key": "0fdde3e5d5ac59e758a2cb7fcd5b0eaa",
      "line": 92,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 17,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The development of dense-core amyloid plaques is associated with a robust immune response mediated by microglial cells.",
      "key": "ff38b59c4c361cbb03382bbfe061e573",
      "line": 81,
      "relation": "association",
      "source": 28,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The appearance of amyloid deposition in the AD brain coincides with a dramatic phenotypic activation of microglial cells in the surrounding area.",
      "key": "339ef9b1054476bb1ca58b316278c929",
      "line": 387,
      "relation": "positiveCorrelation",
      "source": 28,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The deposition of fibrillar Ab in the AD brain results in the recruitment of microglia to the plaques owing to their expression of CCL2, which acts to attract microglia [82].",
      "key": "2415faff7537c4fb9ec5caca5613bbb6",
      "line": 394,
      "relation": "increases",
      "source": 54,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "In the past decade, drugs targeting the NRs, peroxisome proliferator-activated receptor g (PPARg) and liver X receptor (LXR) have shown to ameliorate pathogenesis in animal models of AD.",
      "key": "25a0d76c6f721eb03441089ec446210b",
      "line": 98,
      "relation": "increases",
      "source": 67,
      "subject": {
        "modifier": "Activity"
      },
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Recently, they have been shown to promote the degradation of the Ab peptides in the brain by activating genes responsible for reverse cholesterol transport [13].",
      "key": "26ba0cc8ca1ec2620b07a2a924bd2e7d",
      "line": 105,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 67,
      "subject": {
        "modifier": "Activity"
      },
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Recently, they have been shown to promote the degradation of the Ab peptides in the brain by activating genes responsible for reverse cholesterol transport [13].",
      "key": "01201f62687dfae94a20d986f6347a13",
      "line": 107,
      "relation": "increases",
      "source": 67,
      "subject": {
        "modifier": "Activity"
      },
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Activation of these receptors has been shown to suppress microglial-mediated inflammatory responses both in vitro and in vivo.",
      "key": "b30613dcd7a5a6de85bdec607f447b5e",
      "line": 113,
      "relation": "decreases",
      "source": 67,
      "subject": {
        "modifier": "Activity"
      },
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21]. ",
      "key": "ce21b29fe808709f8e8d26e43b36367c",
      "line": 144,
      "relation": "association",
      "source": 67,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21]. ",
      "key": "99d087ce04f87cf6b8f0e9a313bc157d",
      "line": 145,
      "relation": "increases",
      "source": 67,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21]. ",
      "key": "dafc6061f35ed55f5a19e355c10dc37e",
      "line": 146,
      "relation": "association",
      "source": 67,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21]. ",
      "key": "89c6d56beaef48609c04bb7499513321",
      "line": 147,
      "relation": "association",
      "source": 67,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Numerous studies have shown that both PPAR-g and LXRs induce the expression of ApoE and ABCA1 and it is through the expression of these proteins that they exert their effects on amyloid pathology.",
      "key": "2d98ed32f29edcf10e51a54068c43bd1",
      "line": 181,
      "relation": "increases",
      "source": 67,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Numerous studies have shown that both PPAR-g and LXRs induce the expression of ApoE and ABCA1 and it is through the expression of these proteins that they exert their effects on amyloid pathology.",
      "key": "5a8d77ad3997e0253f3ae72a4ed7bb59",
      "line": 182,
      "relation": "increases",
      "source": 67,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Additionally, PPAR-g can also induce the expression of LXRa creating a metabolically linked cycle.",
      "key": "40139bf8ead6bd0daa32a912ba532b17",
      "line": 240,
      "relation": "increases",
      "source": 67,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Activation of PPAR-g or PPAR-d has been shown to induce Arg1 and IL-4 expression [105,106].",
      "key": "85b070ab27abf21886edbe91716e82bb",
      "line": 413,
      "relation": "increases",
      "source": 67,
      "subject": {
        "modifier": "Activity"
      },
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Activation of PPAR-g or PPAR-d has been shown to induce Arg1 and IL-4 expression [105,106].",
      "key": "5c7a325489c127e7dd58722779ebff0e",
      "line": 414,
      "relation": "increases",
      "source": 67,
      "subject": {
        "modifier": "Activity"
      },
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "In the past decade, drugs targeting the NRs, peroxisome proliferator-activated receptor g (PPARg) and liver X receptor (LXR) have shown to ameliorate pathogenesis in animal models of AD.",
      "key": "25f8cb72705a07aa64f0fec42497f85a",
      "line": 99,
      "relation": "increases",
      "source": 64,
      "subject": {
        "modifier": "Activity"
      },
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Recently, they have been shown to promote the degradation of the Ab peptides in the brain by activating genes responsible for reverse cholesterol transport [13].",
      "key": "209fa75eacd2ad1b3b919843104762fb",
      "line": 106,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 64,
      "subject": {
        "modifier": "Activity"
      },
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "LXR activation increased the ApoE particle size of all human ApoE isoforms, suggesting that activation of this pathways may enhance Ab clearance regardless of the ApoE allele expressed [13].",
      "key": "b4c3f83709ccb082d67ca81b0a1f882d",
      "line": 215,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 64,
      "subject": {
        "modifier": "Activity"
      },
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Recently, they have been shown to promote the degradation of the Ab peptides in the brain by activating genes responsible for reverse cholesterol transport [13].",
      "key": "cc819ec5a6404d57e6012af3661bd77e",
      "line": 108,
      "relation": "increases",
      "source": 64,
      "subject": {
        "modifier": "Activity"
      },
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Activation of these receptors has been shown to suppress microglial-mediated inflammatory responses both in vitro and in vivo.",
      "key": "e810286c5bedd9c98d528b06824ac745",
      "line": 114,
      "relation": "decreases",
      "source": 64,
      "subject": {
        "modifier": "Activity"
      },
      "target": 27
    },
    {
      "key": "3d9c8f475c37382b0b09e4aeb000e5a9",
      "relation": "partOf",
      "source": 64,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "LXR receptors are activated by oxysterols, most prominently hydroxylated forms of cholesterol, and play a critical role in the control of whole body cholesterol homeostasis, as well as exerting potent anti-inflammatory actions [26]. ",
      "key": "35e18fd00edbf3e9599cf70bab8d8500",
      "line": 159,
      "relation": "association",
      "source": 64,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "LXR receptors are activated by oxysterols, most prominently hydroxylated forms of cholesterol, and play a critical role in the control of whole body cholesterol homeostasis, as well as exerting potent anti-inflammatory actions [26]. ",
      "key": "2e35fd55d2099e846a5a9f0e8ee4f171",
      "line": 160,
      "relation": "association",
      "source": 64,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Numerous studies have shown that both PPAR-g and LXRs induce the expression of ApoE and ABCA1 and it is through the expression of these proteins that they exert their effects on amyloid pathology.",
      "key": "99a8c594802d546cc6c462d1fa1cb7f4",
      "line": 183,
      "relation": "increases",
      "source": 64,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "LXR activation increased the ApoE particle size of all human ApoE isoforms, suggesting that activation of this pathways may enhance Ab clearance regardless of the ApoE allele expressed [13].",
      "key": "b45459942d273ebbbfb6683ed235349a",
      "line": 213,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 64,
      "subject": {
        "modifier": "Activity"
      },
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Numerous studies have shown that both PPAR-g and LXRs induce the expression of ApoE and ABCA1 and it is through the expression of these proteins that they exert their effects on amyloid pathology.",
      "key": "e359e4fdca72785f59aa035673751287",
      "line": 184,
      "relation": "increases",
      "source": 64,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "A different result was reported by Vanmierlo et al. who found that LXR agonist treatment resulted in restoration of memory, but did not find a change in plaque burden [48]. ",
      "key": "8dcf9e2b553fd9cce6ed5caf6a267f79",
      "line": 221,
      "relation": "increases",
      "source": 64,
      "subject": {
        "modifier": "Activity"
      },
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Indeed, treatment of AD mouse models with LXR or PPAR agonists has resulted in the suppression of microglial activation [44,45,47,59,63].",
      "key": "bb2a92769a777748f22414171ee356f7",
      "line": 401,
      "relation": "decreases",
      "source": 64,
      "subject": {
        "modifier": "Activity"
      },
      "target": 28
    },
    {
      "key": "b95756a71b527d08689bed38fcd927eb",
      "relation": "partOf",
      "source": 44,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression. ",
      "key": "22d619839a85131e663e6d8966274abb",
      "line": 125,
      "relation": "association",
      "source": 44,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression.",
      "key": "e51ecf9d739b255c79b6a15566ac435d",
      "line": 439,
      "relation": "positiveCorrelation",
      "source": 44,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression. ",
      "key": "0e6d3892593accfd267e7790cb4ddbd8",
      "line": 126,
      "relation": "association",
      "source": 44,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression.",
      "key": "2cc6bd2d35d4954f426dce00893d73f9",
      "line": 440,
      "relation": "positiveCorrelation",
      "source": 44,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression. ",
      "key": "8e26358e392e0f56908b04135b89ded1",
      "line": 127,
      "relation": "association",
      "source": 44,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression.",
      "key": "1e31b083d2da1855c75e1ccea122bd0a",
      "line": 441,
      "relation": "positiveCorrelation",
      "source": 44,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression. ",
      "key": "af399150c7814b99986bcc83536903c2",
      "line": 128,
      "relation": "association",
      "source": 44,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression.",
      "key": "de7b7c2589df10aa8212d37428679295",
      "line": 442,
      "relation": "positiveCorrelation",
      "source": 44,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "They act as dominant regulators of lipid metabolism through their ability to transactivate genes encoding enzymes of lipid metabolism, providing a key linkage between the diet and the genome.",
      "key": "7177d62033859809813f2e22434ab596",
      "line": 134,
      "relation": "regulates",
      "source": 44,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Indeed, treatment of AD mouse models with LXR or PPAR agonists has resulted in the suppression of microglial activation [44,45,47,59,63].",
      "key": "c8fad14fe27a026fdf16db5abc9e0525",
      "line": 400,
      "relation": "decreases",
      "source": 44,
      "subject": {
        "modifier": "Activity"
      },
      "target": 28
    },
    {
      "key": "43a1156956bd8391cb1c98771c1a0a27",
      "relation": "partOf",
      "source": 46,
      "target": 41
    },
    {
      "key": "401f51228661225f7ba9f92cbbc4f138",
      "relation": "partOf",
      "source": 46,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "RXR activation by numerous ligands has shown to increase levels of both ApoE and ABCA1 in vitro [74-76].",
      "key": "31905190b16a65e9d34022b8ef6735cc",
      "line": 347,
      "relation": "increases",
      "source": 46,
      "subject": {
        "modifier": "Activity"
      },
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "RXR activation by numerous ligands has shown to increase levels of both ApoE and ABCA1 in vitro [74-76].",
      "key": "f899f06e03470d74092dfdbf09e59d33",
      "line": 348,
      "relation": "increases",
      "source": 46,
      "subject": {
        "modifier": "Activity"
      },
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression. ",
      "key": "e426c6f9d8b60130c6276f7090c4fa67",
      "line": 125,
      "relation": "association",
      "source": 39,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression.",
      "key": "2d2367a6b7211d4b9d98224cebd87aaf",
      "line": 439,
      "relation": "positiveCorrelation",
      "source": 39,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21]. ",
      "key": "8c390f962c32d744d35a6e7fbefb6cb9",
      "line": 144,
      "relation": "association",
      "source": 39,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21].",
      "key": "cd9a283ae4025bc6612060bab3f633ff",
      "line": 452,
      "relation": "association",
      "source": 39,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression. ",
      "key": "493241396c2ba0d41ea53982b8d3b3dc",
      "line": 126,
      "relation": "association",
      "source": 21,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression.",
      "key": "a9e38969db1823f6949bc7a12da760a4",
      "line": 440,
      "relation": "positiveCorrelation",
      "source": 21,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression. ",
      "key": "40b7598f4ebb2405edfb5e68c8e264f5",
      "line": 127,
      "relation": "association",
      "source": 31,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression.",
      "key": "cf47bcd44e26ed1314c2b8c3ee9c717e",
      "line": 441,
      "relation": "positiveCorrelation",
      "source": 31,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21]. ",
      "key": "e846837fe41535aa09ba6280cee15c84",
      "line": 146,
      "relation": "association",
      "source": 31,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression. ",
      "key": "69696ff19967a65846837c92e9bca5cf",
      "line": 128,
      "relation": "association",
      "source": 32,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPARs have been shown to play essential roles in energy metabolism, adipocyte differentiation, insulin sensitization and tumor suppression.",
      "key": "03a0f6bc70cf21c3c7b9a9f87c752815",
      "line": 442,
      "relation": "positiveCorrelation",
      "source": 32,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-a is known to regulate lipid oxidation but is not highly expressed in the brain [20]. ",
      "key": "dbfc4cb7e064a0b3a2bda3c1eeb7c336",
      "line": 139,
      "relation": "regulates",
      "source": 65,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-a is known to regulate lipid oxidation but is not highly expressed in the brain [20]. ",
      "key": "c046e632f33ed1b85ca0b67eb023d072",
      "line": 447,
      "relation": "regulates",
      "source": 65,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21]. ",
      "key": "fb1404520b10097fc2d69e27c7b960a9",
      "line": 147,
      "relation": "association",
      "source": 26,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " PPAR-b/-d is the most abundant isoform and plays a role in fatty acid oxidation [22].",
      "key": "cf7121d98c82f01c811a119186a7e537",
      "line": 152,
      "relation": "association",
      "source": 66,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-d activation has also been shown to promote reverse cholesterol transport.",
      "key": "e82fa65fa7bc59e18f375b2d6c0af004",
      "line": 321,
      "relation": "increases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-d activation has also been shown to have robust anti-inflammatory actions [73]. ",
      "key": "239aae4cd6979fc69ea935837f9c011f",
      "line": 342,
      "relation": "increases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Activation of PPAR-g or PPAR-d has been shown to induce Arg1 and IL-4 expression [105,106].",
      "key": "34e2da0f641bde085c54eada1da687d9",
      "line": 415,
      "relation": "increases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Activation of PPAR-g or PPAR-d has been shown to induce Arg1 and IL-4 expression [105,106].",
      "key": "ea565a47da742c66805995abac390ff2",
      "line": 416,
      "relation": "increases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " PPAR-b/-d is the most abundant isoform and plays a role in fatty acid oxidation [22].",
      "key": "8c5270b8b56fec5e0a47a976f100c9db",
      "line": 152,
      "relation": "association",
      "source": 22,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "LXR receptors are activated by oxysterols, most prominently hydroxylated forms of cholesterol, and play a critical role in the control of whole body cholesterol homeostasis, as well as exerting potent anti-inflammatory actions [26]. ",
      "key": "e4da965b4540e8bd3b13c8f04f2edfdd",
      "line": 158,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 10,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "LXR receptors are activated by oxysterols, most prominently hydroxylated forms of cholesterol, and play a critical role in the control of whole body cholesterol homeostasis, as well as exerting potent anti-inflammatory actions [26].",
      "key": "a8adc73f9ceacb140edceb4f703866cf",
      "line": 461,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 10,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "LXR receptors are activated by oxysterols, most prominently hydroxylated forms of cholesterol, and play a critical role in the control of whole body cholesterol homeostasis, as well as exerting potent anti-inflammatory actions [26]. ",
      "key": "0edce5c5dc555a33fdcbb10efa7665d3",
      "line": 159,
      "relation": "association",
      "source": 20,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "LXR receptors are activated by oxysterols, most prominently hydroxylated forms of cholesterol, and play a critical role in the control of whole body cholesterol homeostasis, as well as exerting potent anti-inflammatory actions [26]. ",
      "key": "b3f4b458878b16932ad870f049a73c9f",
      "line": 160,
      "relation": "association",
      "source": 29,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The ApoE4 allele is most important genetic risk factor for AD, while the ApoE2 allele is thought to be protective. ",
      "key": "a8cbf29a9b2ad8b001140f75112cdf7f",
      "line": 165,
      "relation": "positiveCorrelation",
      "source": 43,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The ApoE4 allele is most important genetic risk factor for AD, while the ApoE2 allele is thought to be protective.",
      "key": "5803f42495406e2a2b2bd5e31cf2630b",
      "line": 466,
      "relation": "association",
      "source": 43,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Mice expressing the ApoE4 isoform exhibited higher levels of Ab deposition in comparison to ApoE3 or ApoE2 expressing animals [36].",
      "key": "72ef7f06767bfa00c565d30bb8d7a896",
      "line": 170,
      "relation": "increases",
      "source": 43,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "ApoE acts to scaffold the formation of high-density lipoproteins (HDL) that function to transport cholesterol and lipids throughout the body and in the brain. ",
      "key": "d8b92140224546f45bc201a7eabd0771",
      "line": 175,
      "relation": "increases",
      "source": 50,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " They were able to show that the lipidation of ApoE enhanced the degradation of soluble species of Ab by neprilysin in the endolytic compartments of microglia as well as extracellularly through the actions of the insulindegrading enzyme (IDE) [13]. ",
      "key": "c6f8337fb0aaa99044acc7f90b180b9b",
      "line": 190,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 50,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "LXR activation increased the ApoE particle size of all human ApoE isoforms, suggesting that activation of this pathways may enhance Ab clearance regardless of the ApoE allele expressed [13].",
      "key": "00e6f0fa57b3d0790bd2527a7aaed607",
      "line": 214,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 50,
      "subject": {
        "modifier": "Activity"
      },
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The loss of abca1 resulted in not only the reduction of ApoE levels but also a paradoxical increase in Ab deposition in the brain parenchyma of these animals owing to enhanced deposition of poorly lipidated ApoE in the brain [50-52].",
      "key": "53f8acdb35ad67a3bc32829b0a953824",
      "line": 227,
      "relation": "increases",
      "source": 47,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The loss of abca1 resulted in not only the reduction of ApoE levels but also a paradoxical increase in Ab deposition in the brain parenchyma of these animals owing to enhanced deposition of poorly lipidated ApoE in the brain [50-52].",
      "key": "4094ebe3afaa5173e69f98424839ac2b",
      "line": 228,
      "relation": "decreases",
      "source": 47,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Microglia": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " They were able to show that the lipidation of ApoE enhanced the degradation of soluble species of Ab by neprilysin in the endolytic compartments of microglia as well as extracellularly through the actions of the insulindegrading enzyme (IDE) [13]. ",
      "key": "b27f00954821049d7c6ec912e74b7fd5",
      "line": 192,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 63,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " They were able to show that the lipidation of ApoE enhanced the degradation of soluble species of Ab by neprilysin in the endolytic compartments of microglia as well as extracellularly through the actions of the insulindegrading enzyme (IDE) [13]. ",
      "key": "72ac4d368128284e6a79e8e9eccaaac0",
      "line": 194,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 55,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Importantly, this study utilized the LXR agonist, GW3965, to activate the LXRs and induce the expression of both ApoE and ABCA1.",
      "key": "0e72b0d7d94f186582fa806649528091",
      "line": 199,
      "object": {
        "modifier": "Activity"
      },
      "relation": "directlyIncreases",
      "source": 0,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Similarly, stimulation of microglia with the LXR agonist, GW3965, acts simultaneously to suppress inflammation and promote fibrillar Ab stimulated phagocytosis [47].",
      "key": "b53cd43c3d7b092f71fb56553b78a87b",
      "line": 422,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 0,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Importantly, this study utilized the LXR agonist, GW3965, to activate the LXRs and induce the expression of both ApoE and ABCA1.",
      "key": "e68dfe10cc10b3b02071e0dfef646439",
      "line": 200,
      "relation": "increases",
      "source": 0,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Importantly, this study utilized the LXR agonist, GW3965, to activate the LXRs and induce the expression of both ApoE and ABCA1.",
      "key": "edecaf3d1bc2c43bd0095deb587b26ac",
      "line": 201,
      "relation": "increases",
      "source": 0,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Significantly, a 4-month treatment of Tg2576 mice with GW3965 reduced plaque deposition by > 50% and improved contextual memory in these animals [13].",
      "key": "17dab8c2b4f15a00cab4f74fac440cca",
      "line": 206,
      "relation": "decreases",
      "source": 0,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Significantly, a 4-month treatment of Tg2576 mice with GW3965 reduced plaque deposition by > 50% and improved contextual memory in these animals [13].",
      "key": "12cd4a9708dea42831940551e8067556",
      "line": 207,
      "relation": "increases",
      "source": 0,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Similarly, stimulation of microglia with the LXR agonist, GW3965, acts simultaneously to suppress inflammation and promote fibrillar Ab stimulated phagocytosis [47].",
      "key": "bd64af7b618ef0bb04164017cc06c8e8",
      "line": 423,
      "relation": "decreases",
      "source": 0,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Similarly, stimulation of microglia with the LXR agonist, GW3965, acts simultaneously to suppress inflammation and promote fibrillar Ab stimulated phagocytosis [47].",
      "key": "54139f62f5f84cd7653ce8c34290e4de",
      "line": 424,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 0,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Similarly, stimulation of microglia with the LXR agonist, GW3965, acts simultaneously to suppress inflammation and promote fibrillar Ab stimulated phagocytosis [47].",
      "key": "b2b83f4dfe7d9984af2a86fb9b1bf5bd",
      "line": 425,
      "relation": "increases",
      "source": 0,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Conversely, overexpression of ABCA1 in a mouse model of AD was shown to decrease both soluble and fibrillar pools of Ab in 12-month-old mice and reduce plaque burden [53].",
      "key": "370ff5e91ff62db19fac7453a8824e76",
      "line": 234,
      "relation": "decreases",
      "source": 71,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Conversely, overexpression of ABCA1 in a mouse model of AD was shown to decrease both soluble and fibrillar pools of Ab in 12-month-old mice and reduce plaque burden [53].",
      "key": "3bb27ffc817e7ef8bef43956abf0289c",
      "line": 235,
      "relation": "decreases",
      "source": 71,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The deposition of fibrillar Ab in the AD brain results in the recruitment of microglia to the plaques owing to their expression of CCL2, which acts to attract microglia [82].",
      "key": "8d7330d729cb02126d2947ff513d0150",
      "line": 393,
      "relation": "increases",
      "source": 15,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The deposition of fibrillar Ab in the AD brain results in the recruitment of microglia to the plaques owing to their expression of CCL2, which acts to attract microglia [82].",
      "key": "8ff9f65f1ab296943dee3126c48517dd",
      "line": 395,
      "relation": "increases",
      "source": 15,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Similarly, stimulation of microglia with the LXR agonist, GW3965, acts simultaneously to suppress inflammation and promote fibrillar Ab stimulated phagocytosis [47].",
      "key": "0f3254feb3e3e188c944048fe1888243",
      "line": 426,
      "relation": "increases",
      "source": 15,
      "subject": {
        "modifier": "Activity"
      },
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The synthetic TZD PPAR-g agonists are widely prescribed for the treatment of type 2 diabetes mellitus, and have also been shown to be efficacious in a number of CNS disease models [21]. Currently, two TZD agonists, Actos (pioglitazone) and Avandia (rosiglitazone), are FDA approved for the treatment of diabetes.",
      "key": "bcbab943c0cda6e9e827a2f103cacbd2",
      "line": 248,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 11,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The synthetic TZD PPAR-g agonists are widely prescribed for the treatment of type 2 diabetes mellitus, and have also been shown to be efficacious in a number of CNS disease models [21]. Currently, two TZD agonists, Actos (pioglitazone) and Avandia (rosiglitazone), are FDA approved for the treatment of diabetes.",
      "key": "e000539232802f25c6d9840976d00f64",
      "line": 250,
      "relation": "decreases",
      "source": 11,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " When a higher dose of pioglitazone (7 days/40 mg/kg/day) was used in 10-monthold transgenic mice overexpressing the APP V717I mutation, a 20-- 25% decrease in plaque burden was observed with significant reduction in Ab42 levels within the brains of these animals [61].",
      "key": "7163cb1cde2cb3b361507bf498a37efa",
      "line": 257,
      "relation": "decreases",
      "source": 11,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Furthermore, the treatment of APP/PS1 mouse model of AD with pioglitazone (80 mg/kg/day) for 9 days lowered plaque burden by ~ 50% and reversed behavioral deficits in contextual fear conditioning assay. ",
      "key": "4bc39625d85ac0bbf938f5baac42f5db",
      "line": 295,
      "relation": "decreases",
      "source": 11,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " When a higher dose of pioglitazone (7 days/40 mg/kg/day) was used in 10-monthold transgenic mice overexpressing the APP V717I mutation, a 20-- 25% decrease in plaque burden was observed with significant reduction in Ab42 levels within the brains of these animals [61].",
      "key": "c538b64917ecbf95db511bd8aa438399",
      "line": 258,
      "relation": "decreases",
      "source": 11,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Furthermore, the treatment of APP/PS1 mouse model of AD with pioglitazone (80 mg/kg/day) for 9 days lowered plaque burden by ~ 50% and reversed behavioral deficits in contextual fear conditioning assay. ",
      "key": "96f1904832e2d440bb4ee673c2ad18a4",
      "line": 296,
      "relation": "increases",
      "source": 11,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Significantly, the levels of ABCA1 and ApoE were elevated in the brains of these animals [66].",
      "key": "460b00b1dc4ea07795c503565c0d7a2b",
      "line": 302,
      "relation": "increases",
      "source": 11,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Significantly, the levels of ABCA1 and ApoE were elevated in the brains of these animals [66].",
      "key": "edfb06a7b96c7df5f5da73a145225bf6",
      "line": 303,
      "relation": "increases",
      "source": 11,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "In this study, pioglitazone treatment was shown to improve memory and cognition in these patients [67,68].",
      "key": "6a65e89fb678a39c53f58d172059438d",
      "line": 308,
      "relation": "increases",
      "source": 11,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "In this study, pioglitazone treatment was shown to improve memory and cognition in these patients [67,68].",
      "key": "2087620f9e76d67c92d6df64414df693",
      "line": 309,
      "relation": "increases",
      "source": 11,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The synthetic TZD PPAR-g agonists are widely prescribed for the treatment of type 2 diabetes mellitus, and have also been shown to be efficacious in a number of CNS disease models [21]. Currently, two TZD agonists, Actos (pioglitazone) and Avandia (rosiglitazone), are FDA approved for the treatment of diabetes.",
      "key": "6ecd4825a89c88b31a66a086e628d07a",
      "line": 249,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 12,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Pedersen and Flynn examined the effects of rosiglitazone and found that activation of PPAR-g ameliorated behavioral deficits in the Tg2576 AD mouse model. However, these animals displayed no changes in plaque pathology, but had reduced brain Ab42 levels. ",
      "key": "58532dfde9899b1a1f4e9b444aec4dd3",
      "line": 264,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 12,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The synthetic TZD PPAR-g agonists are widely prescribed for the treatment of type 2 diabetes mellitus, and have also been shown to be efficacious in a number of CNS disease models [21]. Currently, two TZD agonists, Actos (pioglitazone) and Avandia (rosiglitazone), are FDA approved for the treatment of diabetes.",
      "key": "8b2a4a0d62f4b91039bc9329f5b94569",
      "line": 251,
      "relation": "decreases",
      "source": 12,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Pedersen and Flynn examined the effects of rosiglitazone and found that activation of PPAR-g ameliorated behavioral deficits in the Tg2576 AD mouse model. However, these animals displayed no changes in plaque pathology, but had reduced brain Ab42 levels. ",
      "key": "eddc90336e835d1ca9f4aed850617ac0",
      "line": 265,
      "relation": "increases",
      "source": 12,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Pedersen and Flynn examined the effects of rosiglitazone and found that activation of PPAR-g ameliorated behavioral deficits in the Tg2576 AD mouse model. However, these animals displayed no changes in plaque pathology, but had reduced brain Ab42 levels. ",
      "key": "afcdb9c97285e059bc98e87f451ac3b7",
      "line": 266,
      "relation": "causesNoChange",
      "source": 12,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " These animals were treated with a low dose of rosiglitazone (3 mg/kg/ day) for 12 weeks and evaluated for plaque deposition and behavior. These animals displayed an approximate 50% decrease in amyloid deposition, a decrease in Ab oligomers, preservation of pre and postsynaptic proteins and the attenuation of cognitive deficits in the Morris water maze. ",
      "key": "87cb9af6427fd8fa37682f5ec183933b",
      "line": 274,
      "relation": "decreases",
      "source": 12,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Pedersen and Flynn examined the effects of rosiglitazone and found that activation of PPAR-g ameliorated behavioral deficits in the Tg2576 AD mouse model. However, these animals displayed no changes in plaque pathology, but had reduced brain Ab42 levels. ",
      "key": "2e04a1dea784794e6717b2c428566c4e",
      "line": 267,
      "relation": "decreases",
      "source": 12,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " These animals were treated with a low dose of rosiglitazone (3 mg/kg/ day) for 12 weeks and evaluated for plaque deposition and behavior. These animals displayed an approximate 50% decrease in amyloid deposition, a decrease in Ab oligomers, preservation of pre and postsynaptic proteins and the attenuation of cognitive deficits in the Morris water maze. ",
      "key": "a0eb8181942c80e7db57ae4408773fed",
      "line": 275,
      "relation": "decreases",
      "source": 12,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " These animals were treated with a low dose of rosiglitazone (3 mg/kg/ day) for 12 weeks and evaluated for plaque deposition and behavior. These animals displayed an approximate 50% decrease in amyloid deposition, a decrease in Ab oligomers, preservation of pre and postsynaptic proteins and the attenuation of cognitive deficits in the Morris water maze. ",
      "key": "a764dfb3e8bc7592f9ff2c65d6935102",
      "line": 276,
      "relation": "increases",
      "source": 12,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " The authors argue that the effects of rosiglitazone were due to the activation of the wnt signaling cascade which they show by an increase in b-catenin expression and a decrease in GSK-3b levels [63].",
      "key": "3af4cd25585578a15707c09c98d5ec72",
      "line": 282,
      "relation": "increases",
      "source": 12,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " The authors argue that the effects of rosiglitazone were due to the activation of the wnt signaling cascade which they show by an increase in b-catenin expression and a decrease in GSK-3b levels [63].",
      "key": "affbb88a6f562a28c0cd0f1800a8aa1d",
      "line": 283,
      "relation": "decreases",
      "source": 12,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "While the authors did not detect an increase in ApoE levels in the treated animals, they did observe a modest increase in ABCA1 levels and argue that the enhanced Ab clearance could be attributed to an increase in lipidation of ApoE by ABCA1 [64]. ",
      "key": "f0a452024a9a723de4827c68904194ab",
      "line": 289,
      "relation": "increases",
      "source": 12,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " A Phase II clinical trial in which patients were treated with rosiglitazone for 6 months showed improvements in attention and memory retention, but only in patients who did not have an APOE4 allele.",
      "key": "23cb657b264744fa0af15867befbe18a",
      "line": 315,
      "relation": "increases",
      "source": 12,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " A Phase II clinical trial in which patients were treated with rosiglitazone for 6 months showed improvements in attention and memory retention, but only in patients who did not have an APOE4 allele.",
      "key": "737bf57b9924bba2dd6ffe7f8044b1c0",
      "line": 316,
      "relation": "increases",
      "source": 12,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The PPAR-d agonist GW501516 induced expression of ABCA1 and apolipoprotein A1, a peripheral lipid transporter, in macrophages [71]. ",
      "key": "64f65736e01da00d7e44304964e4dec9",
      "line": 326,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 1,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The PPAR-d agonist GW501516 induced expression of ABCA1 and apolipoprotein A1, a peripheral lipid transporter, in macrophages [71]. ",
      "key": "ffebe2fb68afce7802c273687e72a41c",
      "line": 327,
      "relation": "increases",
      "source": 1,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The PPAR-d agonist GW501516 induced expression of ABCA1 and apolipoprotein A1, a peripheral lipid transporter, in macrophages [71]. ",
      "key": "b3b868207c9735a5c0ae7e0a287eea39",
      "line": 328,
      "relation": "increases",
      "source": 1,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "In a study reported by Kalinin et al., treatment of 5xFAD mice with the PPAR-d agonist, GW742, resulted in decreased plaque burden and an increase in the expression of two Ab proteases, neprilysin and IDE [72].",
      "key": "cf5648c6c8bfb80f7f4a961902540a6b",
      "line": 335,
      "relation": "decreases",
      "source": 1,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "In a study reported by Kalinin et al., treatment of 5xFAD mice with the PPAR-d agonist, GW742, resulted in decreased plaque burden and an increase in the expression of two Ab proteases, neprilysin and IDE [72].",
      "key": "6989c99710b27baf4fe2cbcad988c868",
      "line": 336,
      "relation": "increases",
      "source": 1,
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "In a study reported by Kalinin et al., treatment of 5xFAD mice with the PPAR-d agonist, GW742, resulted in decreased plaque burden and an increase in the expression of two Ab proteases, neprilysin and IDE [72].",
      "key": "5d5eb144d14b1106c1ef7a29a41fad5d",
      "line": 337,
      "relation": "increases",
      "source": 1,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " ATRA not only activates RXR but also activates the retinoic acid receptor. ",
      "key": "62f9f259c0a6c323f102108aca907797",
      "line": 353,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 2,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " ATRA not only activates RXR but also activates the retinoic acid receptor. ",
      "key": "d3f928a47311aafb5f3e4df6e9ed5ce9",
      "line": 354,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 2,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Treatment of 5-month-old APP/PS1 mice for 8 weeks with ATRA (20 mg/kg/day) resulted in significant decreases in Ab deposition and tau phosphorylation in these mice. Additionally, it attenuated memory deficits seen in the Morris water maze [77]. ",
      "key": "186d862018cfa15c63e586cb629eb8ac",
      "line": 360,
      "relation": "decreases",
      "source": 2,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Treatment of 5-month-old APP/PS1 mice for 8 weeks with ATRA (20 mg/kg/day) resulted in significant decreases in Ab deposition and tau phosphorylation in these mice. Additionally, it attenuated memory deficits seen in the Morris water maze [77]. ",
      "key": "9bbb7b964257f8e688f73f4d93eb7cf3",
      "line": 361,
      "relation": "decreases",
      "source": 2,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " Treatment of 5-month-old APP/PS1 mice for 8 weeks with ATRA (20 mg/kg/day) resulted in significant decreases in Ab deposition and tau phosphorylation in these mice. Additionally, it attenuated memory deficits seen in the Morris water maze [77]. ",
      "key": "196d3bdf0a0d4a627a528ec248c1f38c",
      "line": 362,
      "relation": "increases",
      "source": 2,
      "target": 37
    },
    {
      "key": "064f60bbd4e86ec0d71e89e733af2e71",
      "relation": "hasVariant",
      "source": 61,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Bexarotene is a highly specific RXR agonist and is currently FDA approved with a favorable side effect profile. Studies in our laboratory have shown that treatment of APP/ PS1 animals with bexarotene for only 3 days results in a dramatic induction of ApoE and ABCA1 and the rapid reversal of AD-associated pathological hallmarks including reduction in amyloid deposition and deficits in behavior as well as neural networks.",
      "key": "054651b4b21c4cdb38f4e0110e77bb89",
      "line": 369,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 8,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Bexarotene is a highly specific RXR agonist and is currently FDA approved with a favorable side effect profile. Studies in our laboratory have shown that treatment of APP/ PS1 animals with bexarotene for only 3 days results in a dramatic induction of ApoE and ABCA1 and the rapid reversal of AD-associated pathological hallmarks including reduction in amyloid deposition and deficits in behavior as well as neural networks.",
      "key": "9dc3a2e32651092ee731277f6876e531",
      "line": 370,
      "relation": "increases",
      "source": 8,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Bexarotene is a highly specific RXR agonist and is currently FDA approved with a favorable side effect profile. Studies in our laboratory have shown that treatment of APP/ PS1 animals with bexarotene for only 3 days results in a dramatic induction of ApoE and ABCA1 and the rapid reversal of AD-associated pathological hallmarks including reduction in amyloid deposition and deficits in behavior as well as neural networks.",
      "key": "563b82ea19e86803aa69856f7388d063",
      "line": 371,
      "relation": "increases",
      "source": 8,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Bexarotene is a highly specific RXR agonist and is currently FDA approved with a favorable side effect profile. Studies in our laboratory have shown that treatment of APP/ PS1 animals with bexarotene for only 3 days results in a dramatic induction of ApoE and ABCA1 and the rapid reversal of AD-associated pathological hallmarks including reduction in amyloid deposition and deficits in behavior as well as neural networks.",
      "key": "e59f94ce16fd58d91acd097ab3d4ee9b",
      "line": 372,
      "relation": "decreases",
      "source": 8,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "Bexarotene is a highly specific RXR agonist and is currently FDA approved with a favorable side effect profile. Studies in our laboratory have shown that treatment of APP/ PS1 animals with bexarotene for only 3 days results in a dramatic induction of ApoE and ABCA1 and the rapid reversal of AD-associated pathological hallmarks including reduction in amyloid deposition and deficits in behavior as well as neural networks.",
      "key": "40c874c546042ecc1ac6f8419683bfdf",
      "line": 373,
      "relation": "increases",
      "source": 8,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " More recently, a naturally occurring RXR agonist, honokiol, has been identified. This agonist is capable of activating RXR/LXR heterodimers and has been shown to induce the expression of ABCA1 and ApoE and should be tested in AD models [75,78].",
      "key": "c626c0efce690c5d9978ca3b65273801",
      "line": 379,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 7,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " More recently, a naturally occurring RXR agonist, honokiol, has been identified. This agonist is capable of activating RXR/LXR heterodimers and has been shown to induce the expression of ABCA1 and ApoE and should be tested in AD models [75,78].",
      "key": "c8fd21297fd56dfb758ef5b9893a5b92",
      "line": 380,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 7,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " More recently, a naturally occurring RXR agonist, honokiol, has been identified. This agonist is capable of activating RXR/LXR heterodimers and has been shown to induce the expression of ABCA1 and ApoE and should be tested in AD models [75,78].",
      "key": "723edefeb1b5f76b76402705b7e0d06f",
      "line": 381,
      "relation": "increases",
      "source": 7,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": " More recently, a naturally occurring RXR agonist, honokiol, has been identified. This agonist is capable of activating RXR/LXR heterodimers and has been shown to induce the expression of ABCA1 and ApoE and should be tested in AD models [75,78].",
      "key": "03b72f8e13af34a8d778c80d8d3ec896",
      "line": 382,
      "relation": "increases",
      "source": 7,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "  In this study, it was shown that samples from human AD brains as well as two aged mouse models of AD showed increased mRNA levels of the M2 markers, Arg1 and Ym1, when compared to age matched controls [101].",
      "key": "b85bbb15bf338667fc8d93eb2c78ac0a",
      "line": 407,
      "relation": "positiveCorrelation",
      "source": 80,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "  In this study, it was shown that samples from human AD brains as well as two aged mouse models of AD showed increased mRNA levels of the M2 markers, Arg1 and Ym1, when compared to age matched controls [101].",
      "key": "1c18d4614a90e42b76bc3fe15e95769a",
      "line": 408,
      "relation": "positiveCorrelation",
      "source": 81,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The Ab peptide is generated by the sequential cleavage of the amyloid precursor protein (APP) by the b and g secretases, resulting in the generation of peptides 40 or 42 amino acids in length [2].",
      "key": "defdb517ad30c994bd795d2a70f30616",
      "line": 431,
      "relation": "decreases",
      "source": 53,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The Ab peptide is generated by the sequential cleavage of the amyloid precursor protein (APP) by the b and g secretases, resulting in the generation of peptides 40 or 42 amino acids in length [2].",
      "key": "9880745cc2a74f5d3d32d2727d8bb9bf",
      "line": 433,
      "relation": "increases",
      "source": 53,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The Ab peptide is generated by the sequential cleavage of the amyloid precursor protein (APP) by the b and g secretases, resulting in the generation of peptides 40 or 42 amino acids in length [2].",
      "key": "c123b3ca5650a8e5d33566d005816062",
      "line": 432,
      "relation": "decreases",
      "source": 48,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The Ab peptide is generated by the sequential cleavage of the amyloid precursor protein (APP) by the b and g secretases, resulting in the generation of peptides 40 or 42 amino acids in length [2].",
      "key": "1ffe4c41f58bcc9c8580dc6b70c08fad",
      "line": 434,
      "relation": "increases",
      "source": 48,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21].",
      "key": "fbb8d0970f1fac94b3c8bf5dc9ac8cf4",
      "line": 452,
      "relation": "association",
      "source": 68,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21].",
      "key": "8c1dec6443f2e5f06fb690642a50bad4",
      "line": 453,
      "relation": "association",
      "source": 68,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21].",
      "key": "ed3bc7ba51bff643e8746e351ff544d9",
      "line": 455,
      "relation": "increases",
      "source": 68,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "PPAR-g is involved in lipid storage, insulin sensitivity and energy metabolism and has been shown to promote adipocyte differentiation [21].",
      "key": "b312b3793c08433550f2fc98484ad474",
      "line": 453,
      "relation": "association",
      "source": 77,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "LXR receptors are activated by oxysterols, most prominently hydroxylated forms of cholesterol, and play a critical role in the control of whole body cholesterol homeostasis, as well as exerting potent anti-inflammatory actions [26].",
      "key": "1d028513912bdb7710650d9735c33813",
      "line": 460,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 9,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The M2c macrophages are thought to be in an ‘acquired deactivation’ state induced by IL-10, TGF-b, glucocorticoids or contact with apoptotic cells, and are associated with a suppression of the innate immune response.",
      "key": "6bee4dbd342ad15ca36fe1c40c7c1ba5",
      "line": 471,
      "relation": "decreases",
      "source": 57,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The M2c macrophages are thought to be in an ‘acquired deactivation’ state induced by IL-10, TGF-b, glucocorticoids or contact with apoptotic cells, and are associated with a suppression of the innate immune response.",
      "key": "e7cfe2fcd77edaeeef71ba70f4461b24",
      "line": 472,
      "relation": "decreases",
      "source": 18,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        }
      },
      "citation": {
        "authors": [
          "Landreth GE",
          "Mandrekar-Colucci S"
        ],
        "date": "2011-09-01",
        "db": "PubMed",
        "db_id": "21718217",
        "db_name": "Nuclear receptors as therapeutic targets for Alzheimer's disease.",
        "first": "Mandrekar-Colucci S",
        "journal": "Expert opinion on therapeutic targets",
        "last": "Landreth GE",
        "pages": "1085-97",
        "volume": "15"
      },
      "evidence": "The M2c macrophages are thought to be in an ‘acquired deactivation’ state induced by IL-10, TGF-b, glucocorticoids or contact with apoptotic cells, and are associated with a suppression of the innate immune response.",
      "key": "9830be61f6c25353db58ea84a9ba2eec",
      "line": 473,
      "relation": "decreases",
      "source": 69,
      "target": 19
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"GW 3965\")",
      "concept": {
        "name": "GW 3965",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "fdf70809f19a0940a2a9e6c22a002cac"
    },
    {
      "bel": "a(CHEBI:\"GW 501516\")",
      "concept": {
        "name": "GW 501516",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "bd5ec2c2ed3b32b32b91e11cec093b8d"
    },
    {
      "bel": "a(CHEBI:\"all-trans-retinoic acid\")",
      "concept": {
        "name": "all-trans-retinoic acid",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "c2d6bc6e63a5fc7ca790814563c0aa86"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta polypeptide 40\")",
      "concept": {
        "name": "amyloid-beta polypeptide 40",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "9e0dfb730cc36c0afbaa05a340211fda"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta polypeptide 42\")",
      "concept": {
        "name": "amyloid-beta polypeptide 42",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "ef705fbb8d4e7ba18fb04daf5d329b6b"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta\")",
      "concept": {
        "name": "amyloid-beta",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e9557ea6ec74113b73fe23f4bd76b524"
    },
    {
      "bel": "a(CHEBI:\"high-density lipoprotein\")",
      "concept": {
        "name": "high-density lipoprotein",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "7f7d19ec07813992b8cf2f3e866e2255"
    },
    {
      "bel": "a(CHEBI:Honokiol)",
      "concept": {
        "name": "Honokiol",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "4167d74e2ab136efd5f396a4a974daa5"
    },
    {
      "bel": "a(CHEBI:bexarotene)",
      "concept": {
        "name": "bexarotene",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "1640021d37066a1064f4e1ffe5d07c67"
    },
    {
      "bel": "a(CHEBI:cholesterol)",
      "concept": {
        "name": "cholesterol",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "7b4eb3a8e7365ad199fd92c20e3df8bf"
    },
    {
      "bel": "a(CHEBI:oxysterol)",
      "concept": {
        "name": "oxysterol",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "f9d702f8ac0c917c668138740aab60e6"
    },
    {
      "bel": "a(CHEBI:pioglitazone)",
      "concept": {
        "name": "pioglitazone",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "eacc21602d4ffa2f2227fc5a7b9efbfe"
    },
    {
      "bel": "a(CHEBI:rosiglitazone)",
      "concept": {
        "name": "rosiglitazone",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "f12e54218d48ea9a2e49befce5b12ee6"
    },
    {
      "bel": "a(CONSO:CONSO00018)",
      "concept": {
        "name": "CONSO00018",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "34dd2f1fa683fcd7e9904d4b0d1682d6"
    },
    {
      "bel": "a(CONSO:CONSO00022)",
      "concept": {
        "name": "CONSO00022",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "c2068b8c7525a23f99f35d79eb67734f"
    },
    {
      "bel": "a(CONSO:CONSO00038)",
      "concept": {
        "name": "CONSO00038",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "5a256e19d79cb1ff55c91c6beaa6c54c"
    },
    {
      "bel": "a(CONSO:CONSO00074)",
      "concept": {
        "name": "CONSO00074",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "f604f872fcf65bcd1dee1044511eb8a3"
    },
    {
      "bel": "a(CONSO:CONSO00089)",
      "concept": {
        "name": "CONSO00089",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "b7f3caf8072efcdb4df4de1d1560074c"
    },
    {
      "bel": "a(MESH:Glucocorticoids)",
      "concept": {
        "name": "Glucocorticoids",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "f9bcc0ddc6d566c52744396122b75669"
    },
    {
      "bel": "a(MESH:Macrophages)",
      "concept": {
        "name": "Macrophages",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "311e39dad42597c983d7962f84ee92b6"
    },
    {
      "bel": "bp(GO:\"cholesterol homeostasis\")",
      "concept": {
        "name": "cholesterol homeostasis",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "9e56dfbacc3ef40661a6b6d70f376f34"
    },
    {
      "bel": "bp(GO:\"fat cell differentiation\")",
      "concept": {
        "name": "fat cell differentiation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "d869738eca6844e8005c9344eef723ab"
    },
    {
      "bel": "bp(GO:\"fatty acid oxidation\")",
      "concept": {
        "name": "fatty acid oxidation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "cbe91e0252b1d1ca440d47a0c3805658"
    },
    {
      "bel": "bp(GO:\"learning or memory\")",
      "concept": {
        "name": "learning or memory",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "f7990d886000f2ae69441a960a7d6236"
    },
    {
      "bel": "bp(GO:\"lipid metabolic process\")",
      "concept": {
        "name": "lipid metabolic process",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "14433fae5fad1c2e58790171e548d3b2"
    },
    {
      "bel": "bp(GO:\"lipid oxidation\")",
      "concept": {
        "name": "lipid oxidation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "31a58bef4bd5f778a5bc672ce84e5842"
    },
    {
      "bel": "bp(GO:\"lipid storage\")",
      "concept": {
        "name": "lipid storage",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "1fe41f432faf8cfd44ec99056ff9da2b"
    },
    {
      "bel": "bp(GO:\"microglial cell activation involved in immune response\")",
      "concept": {
        "name": "microglial cell activation involved in immune response",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "d205a259796e05053eab0d47af890dfe"
    },
    {
      "bel": "bp(GO:\"microglial cell activation\")",
      "concept": {
        "name": "microglial cell activation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "3c02f523866973a040dc6bfa5b372b2e"
    },
    {
      "bel": "bp(GO:\"negative regulation of inflammatory response\")",
      "concept": {
        "name": "negative regulation of inflammatory response",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "af66f737bb4f4ce8d18a14347ee8ebd7"
    },
    {
      "bel": "bp(GO:\"neuron death\")",
      "concept": {
        "name": "neuron death",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "5af039c1f3120f7215931236c3c03804"
    },
    {
      "bel": "bp(GO:\"response to insulin\")",
      "concept": {
        "name": "response to insulin",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "4a37b28cd30cb54df4b8cbfdfc9c5bcd"
    },
    {
      "bel": "bp(GO:\"response to tumor cell\")",
      "concept": {
        "name": "response to tumor cell",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "b5c3bfa3e6c76c2f5f4cf27818c8c057"
    },
    {
      "bel": "bp(GO:\"reverse cholesterol transport\")",
      "concept": {
        "name": "reverse cholesterol transport",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "24afa74e45735c2d47d358fd788a8f1b"
    },
    {
      "bel": "bp(GO:\"synaptic signaling\")",
      "concept": {
        "name": "synaptic signaling",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "47e244f71f5d21a426ba920c40e7b9ed"
    },
    {
      "bel": "bp(GO:behavior)",
      "concept": {
        "name": "behavior",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "77f1822074b59deb82cc4661eb6d5aa5"
    },
    {
      "bel": "bp(GO:cognition)",
      "concept": {
        "name": "cognition",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "24220ec2073c35bcd945681ee9c6ea38"
    },
    {
      "bel": "bp(GO:memory)",
      "concept": {
        "name": "memory",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "e03a718b44a1ff30acea5c31966879a9"
    },
    {
      "bel": "bp(GO:phagocytosis)",
      "concept": {
        "name": "phagocytosis",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "7a964edef32244471f3c9f79c2cdfbaf"
    },
    {
      "bel": "bp(MESH:\"Energy Metabolism\")",
      "concept": {
        "name": "Energy Metabolism",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "5aaa959e5040d4765b684841ad0942e1"
    },
    {
      "bel": "bp(MESH:\"Lipid Peroxidation\")",
      "concept": {
        "name": "Lipid Peroxidation",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "5aabe71c6ac7a11f93eabad81eec43ce"
    },
    {
      "bel": "complex(p(FPLX:PPAR), p(FPLX:RXR))",
      "function": "Complex",
      "id": "0bca4d2e3ac329d7999c97308b255727",
      "members": [
        {
          "bel": "p(FPLX:PPAR)",
          "concept": {
            "name": "PPAR",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "5721625bbce1fa0c38a428594009cc3c"
        },
        {
          "bel": "p(FPLX:RXR)",
          "concept": {
            "name": "RXR",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "87fee9580046b8723fb9a6fcf487078e"
        }
      ]
    },
    {
      "bel": "complex(p(FPLX:RXR), p(HGNC:NR1H3))",
      "function": "Complex",
      "id": "57c5096a3ab5e784bcd42216acfb3881",
      "members": [
        {
          "bel": "p(FPLX:RXR)",
          "concept": {
            "name": "RXR",
            "namespace": "FPLX"
          },
          "function": "Protein",
          "id": "87fee9580046b8723fb9a6fcf487078e"
        },
        {
          "bel": "p(HGNC:NR1H3)",
          "concept": {
            "name": "NR1H3",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "6be40547ba727094fd74d0a418407c94"
        }
      ]
    },
    {
      "bel": "g(CONSO:CONSO00030)",
      "concept": {
        "name": "CONSO00030",
        "namespace": "CONSO"
      },
      "function": "Gene",
      "id": "305ce0d91f05d432d8b903e29c3d8c74"
    },
    {
      "bel": "p(FPLX:PPAR)",
      "concept": {
        "name": "PPAR",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "5721625bbce1fa0c38a428594009cc3c"
    },
    {
      "bel": "p(FPLX:RAR)",
      "concept": {
        "name": "RAR",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "b3fa845af65b02fd703dd55fc7a36ad2"
    },
    {
      "bel": "p(FPLX:RXR)",
      "concept": {
        "name": "RXR",
        "namespace": "FPLX"
      },
      "function": "Protein",
      "id": "87fee9580046b8723fb9a6fcf487078e"
    },
    {
      "bel": "p(HGNC:ABCA1)",
      "concept": {
        "name": "ABCA1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "bf01dad9fb537d183b0484d969d22f6e"
    },
    {
      "bel": "p(HGNC:APH1A)",
      "concept": {
        "name": "APH1A",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7fd4a88ca98bc27d43621b06132d8daf"
    },
    {
      "bel": "p(HGNC:APOA1)",
      "concept": {
        "name": "APOA1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "30c3cb5b5f53261dc658ecd8cf2f8bfa"
    },
    {
      "bel": "p(HGNC:APOE)",
      "concept": {
        "name": "APOE",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "6400bf22ba3f98800eca81c8702b5e39"
    },
    {
      "bel": "p(HGNC:APP)",
      "concept": {
        "name": "APP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "d43ae551265c6b6a27038d0b036848cf"
    },
    {
      "bel": "p(HGNC:ARG1)",
      "concept": {
        "name": "ARG1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5416b564f91296a9bf4f568a38766b9d"
    },
    {
      "bel": "p(HGNC:BACE1)",
      "concept": {
        "name": "BACE1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "334dd03e9a5f223f13995e497b1c156e"
    },
    {
      "bel": "p(HGNC:CCL2)",
      "concept": {
        "name": "CCL2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2a1fddd8526478c2c7edadaa639bbe85"
    },
    {
      "bel": "p(HGNC:IDE)",
      "concept": {
        "name": "IDE",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "1b1adb12a1eb23245eaa21ff477ee4c5"
    },
    {
      "bel": "p(HGNC:IFNG)",
      "concept": {
        "name": "IFNG",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "20367a6ea54ae1032be4f48276f3c524"
    },
    {
      "bel": "p(HGNC:IL10)",
      "concept": {
        "name": "IL10",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e0c41f4b3cb8bef32af4e3217ba8aa12"
    },
    {
      "bel": "p(HGNC:IL1B)",
      "concept": {
        "name": "IL1B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "cca08112d9fcf1a31015f1dbfc30b04c"
    },
    {
      "bel": "p(HGNC:IL4)",
      "concept": {
        "name": "IL4",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "4bf986cc68574441e53aac56e3621b28"
    },
    {
      "bel": "p(HGNC:IL6)",
      "concept": {
        "name": "IL6",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8a1d3c4828c5416eba867c395cc65caa"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a8fb3a87d5a0672c07462bb17c8b0947",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MME)",
      "concept": {
        "name": "MME",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "04750748cf48f0571332caef677ccd34"
    },
    {
      "bel": "p(HGNC:NR1H3)",
      "concept": {
        "name": "NR1H3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "6be40547ba727094fd74d0a418407c94"
    },
    {
      "bel": "p(HGNC:PPARA)",
      "concept": {
        "name": "PPARA",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "e79d7558c9c95c0b46af286735dc815f"
    },
    {
      "bel": "p(HGNC:PPARD)",
      "concept": {
        "name": "PPARD",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "650b6228c44fd9aa89a48c2bdced4e28"
    },
    {
      "bel": "p(HGNC:PPARG)",
      "concept": {
        "name": "PPARG",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "3c576f271f63bfbdadb98704c5b62fff"
    },
    {
      "bel": "p(HGNC:PPARGC1A)",
      "concept": {
        "name": "PPARGC1A",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7c753b05cfed767765b0cad6e032d2f2"
    },
    {
      "bel": "p(HGNC:TGFB1)",
      "concept": {
        "name": "TGFB1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "f1f493c4771241860fc73aaa3bfdad66"
    },
    {
      "bel": "p(HGNC:TNF)",
      "concept": {
        "name": "TNF",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "fdc1c1f5a73c3c992b6eb71ce9b6908e"
    },
    {
      "bel": "p(MGI:Abca1)",
      "concept": {
        "name": "Abca1",
        "namespace": "MGI"
      },
      "function": "Protein",
      "id": "147d4cd4a0dc41c95f2d1b150b93d9ab"
    },
    {
      "bel": "p(MGI:Apoe)",
      "concept": {
        "name": "Apoe",
        "namespace": "MGI"
      },
      "function": "Protein",
      "id": "4233387b3d1a7db2fb0f5c4786ce2b4f"
    },
    {
      "bel": "p(MGI:Ctnnb1)",
      "concept": {
        "name": "Ctnnb1",
        "namespace": "MGI"
      },
      "function": "Protein",
      "id": "52ddf5f4f1a665ab5b15d1de632ad4cb"
    },
    {
      "bel": "p(MGI:Gsk3b)",
      "concept": {
        "name": "Gsk3b",
        "namespace": "MGI"
      },
      "function": "Protein",
      "id": "9a69ae5ce70484110c661850294a1735"
    },
    {
      "bel": "path(MESH:\"Alzheimer Disease\")",
      "concept": {
        "name": "Alzheimer Disease",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2ae8307f5fd59056199369691367cc96"
    },
    {
      "bel": "path(MESH:\"Diabetes Mellitus, Type 2\")",
      "concept": {
        "name": "Diabetes Mellitus, Type 2",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "004cfca0d48ee5daca982cdde676e3dd"
    },
    {
      "bel": "path(MESH:\"Insulin Resistance\")",
      "concept": {
        "name": "Insulin Resistance",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "f83a5507de7240fd0d0a97e29670d78a"
    },
    {
      "bel": "path(MESH:Dementia)",
      "concept": {
        "name": "Dementia",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "f28d9b02ed1946e87cf8dd666d940c09"
    },
    {
      "bel": "path(MESH:Inflammation)",
      "concept": {
        "name": "Inflammation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "10cd96fd4056a5e6c27264e0130e89f9"
    },
    {
      "bel": "r(HGNC:ARG1)",
      "concept": {
        "name": "ARG1",
        "namespace": "HGNC"
      },
      "function": "RNA",
      "id": "521b7d43e7c684e74e9a7bd0ffd70e7a"
    },
    {
      "bel": "r(HGNC:CHI3L1)",
      "concept": {
        "name": "CHI3L1",
        "namespace": "HGNC"
      },
      "function": "RNA",
      "id": "552a12cb55c6580de65aeade1b01a0c8"
    }
  ]
}